Defence Therapeutics CEO letter outlines strategic priorities
Defence Therapeutics said its CEO highlighted recent progress and outlined strategic priorities in a letter to shareholders, noting its next-generation precision oncology therapeutics development using proprietary Accum technology.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.